Cell Therapy News

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy showed encouraging early efficacy among heavily pretreated patients with CD19-positive non-Hodgkin lymphoma, according to study results.

NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with relapsed or refractory non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

NEW ORLEANS — Patients recently treated with bendamustine had significantly lower response rates to subsequent chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, data presented at ASH Annual Meeting and Exposition showed.

Shannon L. Maude, MD, PhD, always knew she wanted to work with children — she just didn’t always know how she could best help them.

Speed matters when it comes to treatment of highly aggressive cancers.

NEW ORLEANS — Chimeric antigen receptor T cells demonstrated acceptable efficacy with no additional safety concerns when administered to patients with non-Hodgkin lymphoma and HIV, retrospective study results showed.

Bone marrow transplant and cellular therapies are the only known curative therapy for many patients with hematologic malignancies or other disorders of blood and immune systems.

NEW ORLEANS — In this video perspective, Samer Al Hadidi, MD, MS, FACP, discusses research evaluating G protein–coupled receptor as a new target for therapy in relapsed refractory multiple myeloma.

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy conferred a 78% complete response rate in patients with heavily pretreated T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, study results showed.